Long-interval dosing of anti-CD20 therapy: Toward affordable treatment for multiple sclerosis
- 16 January 2026
- journal article
- Published by Elsevier in Revue Neurologique
- Vol. 182 (3) , 193-194
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Extended-interval dosing of rituximab/ocrelizumab is associated with a reduced decrease in IgG levels in multiple sclerosisNeurotherapeutics, 2025
- Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosisMed, 2023
- Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple SclerosisNeurology Neuroimmunology & Neuroinflammation, 2022
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisNew England Journal of Medicine, 2017
- Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximabNeurology, 2016
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple SclerosisNew England Journal of Medicine, 2008